Highlights from

WCD 2019

World Congress of Dermatology

Milan 10-15 June 2019

Etanercept biosimilar shows preliminary efficacy in psoriasis and psoriatic arthritis

Preliminary data of a real-life study shows that the etanercept biosimilar SB4 effectively alleviates symptoms of psoriasis and psoriatic arthritis. In addition, the agent was well tolerated.

Currently, not much data is available on the efficacy of the etanercept biosimilar SB4 in patients with psoriasis and psoriatic arthritis. To close this gap, an ongoing single-centre study of the University of Rome is assessing the safety and efficacy of SB4 over a treatment period of 3 years. At the WDC 2019, a preliminary analysis was presented of a treatment period of up to 1 year. Thus far, 91 out of foreseen 350 patients have been enrolled, of whom 52 have already been treated for 1 year, and of those 14 suffered from plaque psoriasis, and 38 from psoriatic arthritis.

Therapy with SB4 led to a remarkable improvement of the Psoriasis Area and Severity Index (PASI). At baseline, patients had a mean PASI of 6.57, which improved to 1.2 until week 24. After 1 year of treatment, patients gained a mean PASI score of 0.8. Likewise, symptoms of psoriatic arthritis, assessed with the Disease Activity Score in 28 Joints (DAS28)/CRP value, diminished from 4.15 at baseline to 2.43 at week 24, and 2.15 at week 52. The biosimilar showed to be well tolerated.

Although this is preliminary data, the authors conclude that SB4 is effective in both reducing symptoms of psoriasis and psoriatic arthritis. The potential reduction in cost could guarantee access to biological therapies for a larger number of patients.

  1. Giunta A, Manfreda V, Esposito M et al. Anti-TNF alpha biosimilars in the treatment of plaque‐type psoriasis and psoriatic arthritis: a real-life single‐center study on effectiveness, safety and pharmacoeconomic impact. Poster presented during the World Congress of Dermatology. Mailand, June 10-15, 2019.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.